Brian R. Murphy

Brian R. Murphy is an American virologist and former co-chief of the Laboratory of Infectious Diseases at the National Institute of Allergy and Infectious Disease.[2]

Brian R. Murphy
Born1942
TitleCo-chief, Laboratory of Infectious Diseases
Academic background
Alma materWesleyan University, University of Rochester Medical School
Academic work
DisciplineVirology, Molecular Biology
Sub-disciplineViral vaccine development
Notable studentsJames E. Crowe ('90-'93)[1]

Education and career

Brian Murphy was born in 1942.[3] He completed his undergraduate B.S. degree from Wesleyan University in 1964. He then went on to medical training, completing his M.D. in 1969 at the University of Rochester Medical School, and internship the next year at Stanford University Hospital.[2] He moved to the National Institutes of Health in 1970 as a research associate in the Laboratory of Infectious Diseases within the National Institute of Allergy and Infectious Disease.[4][2] In 1983, he was promoted to head the respiratory viruses section of the Laboratory of Infectious Diseases.[2] In 2001, he became co-chief of the Laboratory of Infectious Diseases with Robert H. Purcell.[2] He retired from the National Institutes of Health in 2010.[3]

Brian Murphy administers an intranasal flu vaccine during a 1984 clinical trial

Brian Murphy received the inaugural Robert M. Chanock award for lifetime achievements in RSV research at the Respiratory Syncytial Virus 2003 symposium in November 2003.[5]

He served on the editorial board of the Journal of Virology.[6]

Research

Murphy's research has focused on vaccine development for various viruses. In particular, his group is known for working on developing vaccines against respiratory syncytial virus, parainfluenza virus, influenza virus, dengue virus, and West Nile virus.[3][2]

Notable publications
  • Subbarao K, McAuliffe J... Murphy B (2004). Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. Journal of Virology. 78(7): pgs. 3572-3577
  • Wright PF, Karron RA.. Murphy BR (2000). Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. Journal of Infectious Diseases. 182(5): pgs. 1331-1342
  • Collins PL, Hill MG... Murphy BR (1995). Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proceedings of the National Academy of Sciences. 92(25): pgs. 11563-11567
  • Subbarao EK, London W, Murphy BR (1993). A single amino acid in the PB2 gene of influenza A virus is a determinant of host range. Journal of Virology. 67(4): pgs. 1761-1764
  • Clements ML, Betts RF... Murphy BR (1986). Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. Journal of Clinical Microbiology. 24(1): pgs. 157-160

References
  1. "Curriculum Vitae; April 5 2017" (PDF). Vanderbilt University. Retrieved 18 July 2019.
  2. "NIAID Lab Chief Murphy Retires after 40 Years at NIH". NIH Record. 25 June 2010. Retrieved 18 July 2019.
  3. Jamie Kugler (October 2014). "Secrets of Building 7 - NIH's First State-of-the-Art Infectious Disease Laboratory". The Catalyst. Retrieved 18 July 2019.
  4. "The Influenza Viruses and their Vaccines - Seminar Notice". NIH Clinical Center. Retrieved 18 July 2019.
  5. Alexander C. Schmidt, et al, Respiratory syncytial virus and other pneumoviruses: a review of the international symposium—RSV 2003, Virus Research 106 (2004), no. 1, 1-13
  6. Editorial Board, Journal of Virology, 68 (1994), no. 8
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.